Aclaris Therapeutics Stock News

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (

It is a pleasure to report that the Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is up 31% in the last quarter. But that...

•  Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6•  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory.

Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent Milano to its board of directors, effec

From the archive: Was this article in 1913 an early example of ‘native advertising’?

Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Our underpaid MBAs spend a lot of time doing research here at Nanalyze. We want to be as comprehensive as possible to ensure that we’re bringing our lovely readers the best stories about technology

Microsoft has discontinued Kinect for Xbox One. The peripheral originally launched with every new Xbox One console.

Mixed reality has been buzzing the past few weeks with a slew of Microsoft Hololens and Magic Leap announcements. Both companies seem poised to augment our realities over the next few years, but one d